论文部分内容阅读
目的：研究原发性肝癌肝动脉化疗、栓塞的疗效及其影响因素。材料与方法：回顾性分析１８８例肝癌肝动脉化疗、栓塞的临床随访资料。结果：总疗效为症状缓解占５９．６％，肿瘤缩小占５５％，ＡＦＰ下降占３７．８％，半年及１、２、３年生存率分别为７５．４％、４６％、２３．５％、１４．７％，平均生存期１２．２月，最长已存活５０月，获二步手术切除１８例，对比分析了７个影响疗效的有关因素。结论：无或轻度肝硬化、早中期、单个肿瘤、直径＜１０ｃｍ、无门脉癌栓或肝动－静脉瘘、行栓塞治疗、治疗次数在３次以上者，其中远期疗效明显优于对应组。克服有关影响因素及综合治疗将会进一步提高肝癌化疗栓塞的疗效
Objective: To investigate the efficacy and influencing factors of hepatic arterial chemotherapy and embolization in primary liver cancer. Materials and Methods: The clinical follow-up data of 188 hepatic arterial chemotherapy and embolization were retrospectively analyzed. Results: The total efficacy was 59.6% for symptomatic relief, 55% for tumor reduction, and 37.8% for AFP reduction. The half-year and 1-, 2-year survival rates were 75.4%, 46%, and 23.5, respectively. %, 14.7%, the average survival time was 12.2 months, and the longest survival time was 50 months. 18 cases were removed by two-step surgery, and 7 related factors affecting the curative effect were compared and analyzed. Conclusions: No or mild cirrhosis, early-middle-term, single tumor, diameter less than 10cm, portal vein tumor thrombus or hepatic arteriovenous fistula, embolization treatment and treatment times more than 3 times, the long-term efficacy is better than The corresponding group. Overcome related factors and comprehensive treatment will further improve the efficacy of hepatocellular carcinoma chemoembolization